IPP Bureau

Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia
Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia

By IPP Bureau - June 03, 2026

Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market

Abbott highlights prognostic value of MRD testing for breast cancer recurrence
Abbott highlights prognostic value of MRD testing for breast cancer recurrence

By IPP Bureau - June 03, 2026

New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients

Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350

By IPP Bureau - June 03, 2026

DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability

Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business
Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business

By IPP Bureau - June 03, 2026

Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region

CARE Hospitals strengthens advanced cardiac care
CARE Hospitals strengthens advanced cardiac care

By IPP Bureau - June 03, 2026

The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries

Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment
Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment

By IPP Bureau - June 03, 2026

New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure

CORONA Remedies receives EU-GMP certification for hormone facility
CORONA Remedies receives EU-GMP certification for hormone facility

By IPP Bureau - June 02, 2026

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets

Marksans Pharma to acquire Netherlands-based QliniQ
Marksans Pharma to acquire Netherlands-based QliniQ

By IPP Bureau - June 02, 2026

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

By IPP Bureau - June 02, 2026

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death

Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes
Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes

By IPP Bureau - June 02, 2026

Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

By IPP Bureau - June 02, 2026

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary

CellCarta and Leica Biosystems expand push to streamline precision medicine development
CellCarta and Leica Biosystems expand push to streamline precision medicine development

By IPP Bureau - June 02, 2026

The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

By IPP Bureau - June 02, 2026

The safety profile was described as manageable, though not without notable toxicities

Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial

By IPP Bureau - June 02, 2026

The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)

Ebola vax on the anvil?
Ebola vax on the anvil?

By IPP Bureau - June 02, 2026

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate

Latest Stories

Interviews

Packaging